India’s pharma industry — a global generics and manufacturing hub — is using AI to move upstream into discovery and to sharpen its plants, but under intense data-integrity scrutiny. Here’s a grounded view. (dgm implements osFoundry, a separate company’s platform — dgm is an independent integration partner, not osFoundry, and this is not legal advice.)

The use cases

  • AI drug discovery — analysing molecular structures and predicting drug-target interactions, letting India compete “upstream” where IP is created.
  • AI in clinical trials — protocol design, predictive site selection, recruitment; reported to cut timelines (and India’s genetic diversity is a recruitment asset).
  • Generative-AI pharmacovigilance and content — e.g. PV case processing at firms like Indegene.
  • Industrial AI in GxP manufacturing — process optimisation, batch analytics, deviation prediction.
  • Regulatory-submission automation — across the documentation stack.

Data integrity is the defining risk

This is where Indian pharma AI differs from the hype. Data integrity is heavily scrutinised — Indian manufacturing sites have featured prominently in US-FDA data-integrity warning letters, and in April 2026 the FDA issued its first warning letter citing inappropriate AI use in cGMP documentation (Clarkston). The lesson is explicit: AI output must have authorised human review before becoming a controlled GMP record. AI cannot be a black box in a regulated plant. This shapes how AI is deployed far more than whether.

New Indian regulation: CDSCO SaMD guidance

India now regulates this directly: CDSCO’s Draft Guidance on Medical Device Software (21 October 2025) is the first Indian regulation explicitly covering AI/ML and cloud software-as-a-medical-device, requiring change-management protocols, documented retraining triggers, and validation before clinical impact (CDSCO; coverage). Confirm the final version’s status at the time you build.

Where osFoundry fits

osFoundry supports pharma AI workflows — knowledge retrieval, PV and document processing, agents — with a config and audit layer that helps enforce human-in-the-loop review and keep an audit trail, self-hosted for data control. The honest boundary: dgm builds the technical controls; your QA/regulatory team owns GxP and CDSCO determinations. osFoundry is younger with limited independent coverage, so dgm validates fit.

How dgm helps

dgm builds governed pharma AI on osFoundry with the audit trails, human-in-the-loop review and validation GxP and CDSCO expect, self-hosted where required. Transparent pricing: $399 assessment, $3,999/month implementation, no per-seat fees (INR approximate; 18% GST for domestic clients). Explore the platform at osFoundry, or talk to dgm about compliant pharma AI.

General information, not legal or regulatory advice. Confirm CDSCO, GxP and FDA obligations with qualified experts before deploying.